Cytochrome P450 51 (CYP51) is sterol 14a-demethylase, known also as Erg1 l p in yeast. First studied in yeast, where it is one of three CYPs in the genome, it has subsequently gained attention as the only CYP found so far in different kingdoms of life. As such it is central to considerations of CYP evolution. Recent use of CYP51 -inhibiting Key words: azole, cytochrome P450 51, fungi, mycobacteria, sterol. Abbreviations used: CYP, cytochrome P450. 'To whom correspondence should be addressed (e-mail les@aber.ac.uk).
Introduction
Cytochromes P450 (CYPs) are studied extensively and the main engine for the field has been the applied significance of these mono-oxygenase genes/enzymes in drug metabolism, carcino-
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genesis and human biology. Recently greater attention has also turned to the huge diversity of CYPs revealed through the genome projects with animals appearing to use 50-90 enzymes, which are different between species, and plants using around 300 for primary and secondary metabolism. Diversity in CYP number, function and types among the microbes is also clear, Saccharomyces cerevisiae has three, Escherichia coli has none, Bacillus subtilis has seven, the actinomycete Mycobacterium tuberculosis has 20 and they are also present in archaebacteria. Much of this diversity has been driven by the evolution of novel functions and by deterrent/attractant/detoxification strategies in biochemical warfare and reproduction strategies. T h e majority of the known diverse CYP superfamily are orphans in terms of gene function and represent a rich reservoir of catalytic targets for biotransformations, pathway engineering, bioremediation and new therapeutic strategies. Attention has also turned to the origins of the superfamily.
CYPS I is an ancient activity and central to consideration of CYP evolution
T h e value of studies using the yeast S. cerevisiae is now well established, providing as it does fundamental insight into eukaryotic biological systems. This has also been the case for CYP studies where, shortly after the development of yeast cloning methods and gene-disruption techniques, the first essential CYP was demonstrated and related to an activity inhibited by the established azole antifungals, namely sterol 14a-demethylation [l] . T h e protein sequence uncovered in yeast was later matched by orthologous sequence discovery in mammals [2] and also plants [3] and was the first and only (so far) CYP to be found in more than one kingdom of life. Protein sequence identity is used to assign a CYP to a particular family with a general rule of > 40 yo identity being used.
In the case of CYP51 some levels of identity fall beneath that, but assignment to the CYP51 family is maintained where strict catalytic function is retained. Much of the current extensive diversity of the superfamily may have resulted from duplication events arising from CYP51. However, whether it was the original activity in the superfamily, arising as a mono-oxygenase when oxygen appeared in the atmosphere, or the only primordial CYP activity retained to the present day, is unclear, but intriguing. In considering the use of molecular oxygen it should also be noted that squalene epoxidase precedes sterol 14a-demethylase in the sterol pathway and is also a monooxygenase that presumably arose earlier in evolution. I t is the branchpoint of hopanoid and sterol biosynthesis, a distinguishing feature of prokaryotic and eukaryotic biochemistry.
Due to the applied reasons for studying CYP51 in antifungal research, and the postgenomic harvest, many sequences are now available. From these a surprising appearance of a CYPSl-like sequence in M. tuberculosis led us to discover a novel bacterial sterol biosynthetic pathway [4] and the gene product was subsequently shown to have sterol 14a-demethylase activity [5] . Bacteria are not generally thought to produce sterols and this discovery has both fundamental and applied importance, as discussed below. T h e CYP51 sequences can be analysed and a phylogenetic tree constructed (Figure 1 ). T h e tree arranges the proteins in a logical order and sequences that are best represented are the fungi. T h e fungi included are quite distant in evolutionary terms; for instance the lineage to S. cerevisiae and Schizosaccharomyces pombe diverged at least 300 million years ago and possibly in the pre-Cambrian period. T h e mammalian sequences and also the plant sequences are more closely related and cluster as expected, as seen for the grasses. Among the fungi, the ascomycete yeasts cluster as do the filamentous ascomycetes and the basidiomycetes. T h e primitive fungus Cunninghamella elegans appears to be on a separate branch. T h e placing of Dictyostelium discoidum C YP51 on the branches near to plants is open to conjecture related to the position of this protist in the tree of life. More CYP51 sequences from diverse organisms will help build a more comprehensive picture of CYP5 1 evolution, remembering that some organisms including nematodes and insects do not synthesize sterol, presumably through genetic drift in an environment containing a source of sterol (an intriguing evolutionary scenario to consider in itself when that is also true for other organisms). Comparison of intron positions between the currently known genetic loci of C YP5ls does not yield clear further information, as no intron position is conserved throughout.
T h e occurrence of sterol biosynthesis in bacteria, rather than the presence of sterol in cell pellets, has been a vexed question with proof being difficult to establish. Besides the mycobacterial sterol biosynthesis, we recently also detected a CYP51-like sequence in the emerging genome of Streptomyces coelicolor. This sits well with current thought that a divergence from mycobacteria not organized in mycobacteria as an operon. It can occurred only 10 million years ago. Streptomyces be concluded that the horizontal transmission of may also be prokaryotic organisms which make such a genetic system is a remote possibility and sterols. Other reports of sterol biosynthesis in Lthat sterol biosynthesis, and CYP51, may have forms of Staphylococcus aureus [ 6 ] have appeared evolved prior to the separation of the prokaryotic but this genome has revealed no CYP51-like and eukaryotic lineages. sequence to date and the fully compiled genome of one strain is practically finished at the time of writing. E. coli also lacks the necessary genes for sterol biosynthesis, but was earlier reported to make sterols [7] . Sterol biosynthesis is a complex pathway involving over 20 individual steps and is
Concerning divergence from CypS I
As an ancestral CYP, gene-duplication events involving CYP51 are of interest concerning the divergence of the superfamily. S. cerevisiae con- tains three CYPs, a lower number than some other organisms rooted earlier in evolution. Besides CYP51, a second enzyme, CYP61, undertakes sterol 22-desaturation which is one of the last steps of sterol biosynthesis that is essential for the production of the fungal sterol ergosterol. Another, CYP56, is found in meiotic cells producing dityrosine in the yeast spore coat [8] . The sequence of CYP61 was uncovered by the yeast genome project. Amino acid sequence data from purified protein produced in a C YP51-gene-disrupted yeast enabled us to immediately assign a function to this orphan CYP61 on chromosome XIII, namely sterol 22-desaturation [9] . This represented the first example of CYP functional genomics. Surprisingly, the closest CYPs in terms of sequence identity to CYP51 are CYP7 and CYPS [lo] rather than CYP61. However, as we speculated earlier CYP61 probably arose as a duplication event from CYP51 [11, 12 ]. The refinement of sterol structure to include this 22-desaturation confers resistance to osmotic shock and other robustness on yeast which may well have been the selective pressure driving the increasing complexity of the sterol structures in ancient unicellular organisms. We see no clear relationship between this event and the postulated genomeduplication event that has been proposed in yeast [13] , but ergosterol is also produced in algae and protozoa, leading us to again propose here that CYP61 may be discovered in another kingdom of life. However, although plants also produce 22-desaturated sterols in a more diverse complement of end-products than in fungi or animals, no clear CYP61 orthologue is present in Arabidopsis thaliana [14] . Neither is CYP61 present in D . discoidum. Plants and animals do not make ergosterol, but they do make various phytosterols and cholesterol, and as we suggested earlier it is possible that CYP61 was lost in strands of evolution leading to multicellular organisms. An interesting observation concerning CYP61 is the activity of the protein in low-level metabolism of pro-mutagens such as that observed in yeast genotoxicity assays. This activity might have been a starting point in the evolution of xenobiotic-metabolizing CYPs [121*
Other roles for CYPS I ; meiosisactivating sterols
The housekeeping nature of CYP51 in sterol biosynthesis has been the predominant theme of studies over the last two decades. The enzyme undertakes the demethylation reaction in three sequential attacks of the 14a-methyl group [15] and molecular oxygen is utilized in a mechanism seen also for CYP19 (aromatase) and CYP17 [16] . The control of this activity in meiotic mammalian cells has become another important focus as products of CYP51 reactions act as meiosisactivating sterols in sperm and egg production [17] . This has provided a spur for a new field with potential application for fertility manipulation. The role of CYP51 in meiosis elsewhere is something for conjecture. Other roles for CYP51 cannot be ruled out and in A. thaliana two C YP51 genes exist in the genome. Studies on other sterol proteins have indicated they have been adapted to perform roles as cellular receptors such as sigma factor (similar to C8-isomerase) and p-lamin receptors (similar to C14-reductase) and a similar recruitment of CYP should be considered.
CYPS I as a target for bioactive molecules
CYP51 is the target of azole antifungals, but could also be the basis for anti-cholesterol and herbicide design strategies, possibly also having effect on meiosis-activating-sterol production. For 30 years inhibitors of l4a-demethylation have been used in agriculture to combat fungal disease and during the same period, firstly topical treatments and then systemic treatments, became available for medical conditions. The 1980s saw the introduction of ketoconazole and then fluconazole, and later itraconazole became available. The pharmacokinetic and safety profile of fluconazole made it an excellent improvement in treating fungal infection over existing treatments, although the drug lacked activity against aspergillosis and was fungistatic rather than fungicidal. This time also coincided with a dramatic increase in fungal infection associated with immunocompromised patients. Recently fungi have become the third mostabundant agent of hospital-acquired infection. For AIDS patients, life-time and often prophylactic treatment with fluconazole became the norm and soon resistance emerged as a significant problem, occurring in > 10% of late-stage AIDS patients [18] . Resistance also occurred in other settings and with fungi besides Candida albicans [ 
191.
Resistance occurs through sterol mutation in C5-desaturation, increased drug efflux and/or changes in CYP51 itself. The novel mechanism associated with C5-desaturase defects has been
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0 2001 Biochemical Society observed clinically [20] and supports our original hypothesis established in yeast [21, 22] that the accumulation of 14-methylergosta-8,24(28)-dien3p,6a-diol causes growth arrest with azole treatment. Sterol C5-desaturase mutants accumulate 14-methylfecosterol under treatment and can grow, as they can when growing on C5-saturated sterol (ergosta-7,22-dienol) without treatment. Unfortunately this mechanism of azole resistance can confer cross-resistance to amphotericin, the other main alternative for therapy that has a mode of action involving binding to ergosterol. Altered efflux pumps also give rise to resistance, both of the ABC and major facilitator superfamilies [23] , but increasing information has identified CYPSl mutations as causes of resistance. In a survey of resistant clinical C. albicans strains many alterations were detected in the CYPS1 sequence [24] , some now known to be polymorphisms and some causing an alteration in the binding of the drug. Of the point mutations detected, Y132H, S405F, G464S, G465S and R467K all appear able to cause resistance as single mutations; the effect of multiple combinations will need considerable unravelling. Interestingly, none of these changes are where the azole drug was predicted to bind from the earliest modelling of azole binding to C. albicans CYP51, using the CYPlOl structure [25] , where an aromatic interaction with F233 or F235 was predicted. T h e placement of the various mutations within this model has been presented by us [24] , and subsequently others [26] , and also rationalized in subsequent modelling studies [27] . T h e sequence alignment of regions of C. albicans CYP51 associated with resistance is shown in Figure 2 . As we have pointed out, the selection of altered CYP51 was associated with retention of catalytic activity, representing an effective resistance strategy where growth was not drastically impaired.
T h e biochemical evaluation of the inhibition of heterologously expressed mutations G464S [28] , R467K [29] and Y132H [30] has been reported and in all cases an increased quantity of azole was needed to inhibit activity, confirming reduced affinity (correlating with microbiological studies). This was also reflected by altered azole binding to the mutant haemoproteins measured by inhibitor-binding difference spectroscopy. T h e cause of resistance in the case of the mutants located in the haem-binding domain may be through alterations in the position of the haem to which the azole ring of the drug is bound as a sixth ligand. T h e Y132 residue may interact with the of course the cycle of agent discovery and resistance seen with fungi will provide valuable guidance. This is not the only alternative use of these compounds as efficacy also exists against some protist pathogens, e.g. Leishmania.
We have detected an equivalent of the fungal target, sterol 14-demethylase, in the Mycobacterium bovis BCG genome, also representing the orthologous gene to the M . tuberculosis C YP51 with no amino acid differences. Table 1 shows the in vitro activity of a range of azole antifungals against M. bovis BCG, showing both inhibitory efficacy and in some cases bactericidal activity. Mycobacteria were grown in 50ml of Middlebrook 7H9medium for 1 week at 37°C and inoculated at approximately lo3 c.f.u./ml in 5 ml cultures for drug-susceptibility tests. All antifungal compounds showed no activity against E. coli, which lacks sterol biosynthesis, and activity against C. albicans is also shown for reference.
Indeed the activities for many of the compounds were of the same order as those observed in our previous studies on C. albicans. Their activity indicates they are an attractive prospect for antimycobacterial therapy that must be considered closely, as many azoles already have a known
Anti-mycobacterial CYP5 I inhibitors
The discovery of mycobacterial sterol biosynthesis led us to consider the potential for azole and other sterol-inhibiting therapies against these pathogens. Anti-mycobacterial are and acceptable toxicological profile. We have Seen similar results in studies on M . smegmatis [32] .
required to target the serious increase in frequency of multi-drug-resistant tuberculosis (M-DRTB)
Interestingly, no cyp5 is produced in M . leprae.
emerging across the globe. Current therapy involves mainly isoniazid, and resistance to this antibiotic and other limited treatment options have become a major problem [31] . The prospect of utilizing existing anti-fungal compounds of accepted toxicological safety becomes worthy of attention, as well as novel structure-activity studies on new chemicals. Compounds that may show activity could represent a starting point for a new generation of anti-mycobacterial agents and 
Conclusions
CYP5 1 has become the focus of many studies due to the central importance in discussions of CYP evolution and continuing evolution in the face of selective pressure from azole drugs. The other roles of CYP51 are also extremely important and the general relevance of these in other organisms together with a greater appreciation of CYP51 diversity will be clarified in the coming years. Structural information will also be forthcoming that will be of value in understanding the different substrates of CYP51 [33] as well as the basis of inhibition and resistance. The new wave of azole antifungal drugs to replace and/or complement fluconazole usage is imminent and further development of other drugs will occur in the longer term. It may well be that the existing drugs and related compounds will find further uses as antibiotics.
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